Global Sources Ltd. (NASDAQ:GSOL) shares moved up 1.22% in last trading session and ended the day at $8.31. GSOL Gross Margin is 56.70% and its has a return on assets of 5.50%. Global Sources Ltd. (NASDAQ:GSOL) quarterly performance is 0.12%.
On 30 November, Global Sources Ltd. (NASDAQ:GSOL) reported a third-quarter loss of $4.6 million, after reporting a profit in the same period a year earlier. On a per-share basis, the Hamilton, Bermuda-based company said it had a loss of 17 cents. Losses, adjusted for one-time gains and costs, came to 16 cents per share. The producer of marketing Web sites and trade shows posted revenue of $23.5 million in the period.
Northern Tier Energy LP (NYSE:NTI) ended the last trading day at $26.45. Company weekly volatility is calculated as 2.21% and price to cash ratio as 21.43. Northern Tier Energy LP (NYSE:NTI) showed a weekly performance of -2.33%.
Northern Tier Energy LP (NYSE:NTI) announced that Northern Tier management participated in the Cowen and Company 5th Annual Ultimate Energy Conference in New York City on Tuesday, December, 1, 2015.
On 04 December, Acceleron Pharma, Inc. (NASDAQ:XLRN) shares moved up 1.13% and was closed at $42.90. Acceleron Pharma, Inc. (NASDAQ:XLRN) year to date (YTD) performance is 10.11%.
Celgene Corporation (CELG) and Acceleron Pharma Inc. (NASDAQ:XLRN) announced preliminary results from an ongoing long-term Phase 2 extension study in patients with lower risk myelodysplastic syndromes (MDS) at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition. Results highlighted in an oral presentation showed that patients with lower risk MDS treated with luspatercept in the long-term extension study achieved and maintained increased hemoglobin levels and transfusion independence. Celgene and Acceleron are jointly developing luspatercept.
Prima Biomed Ltd. (NASDAQ:PBMD) shares fell -3.97% in last trading session and ended the day at $1.21. Prima Biomed Ltd. (NASDAQ:PBMD) quarterly performance is -6.92%.
On 18 November, Prima BioMed Ltd (NASDAQ: PBMD) unveiled a new clinical trial of IMP321, to be called ‘TACTI-mel’, short for ‘Two ACTive Immunotherapeutics in melanoma’. In this ground-breaking safety and dose finding study IMP321 will be combined with an approved checkpoint inhibitor in patients with metastatic melanoma.
PTC Therapeutics, Inc. (NASDAQ:PTCT) caters to the Healthcare space. Its weekly performance is -6.16%. On the last day of trading company shares ended up at $27.74. PTC Therapeutics, Inc. (NASDAQ:PTCT) distance from 50-day simple moving average (SMA50) is 3.16%.
PTC Therapeutics, Inc. (NASDAQ:PTCT) announced that on December 3, 2015 it approved non-statutory stock options to purchase an aggregate of 57,200 shares of its common stock to 26 new employees. The awards were made pursuant to the NASDAQ inducement grant exception as a component of our new hires’ employment compensation.